|
KMID : 0338420020170040259
|
|
The Korean Journal of Internal Medicine
2002 Volume.17 No. 4 p.259 ~ p.262
|
|
|
Gemcitabine Therapy in Patients with Advanced Pancreatic Cancer
|
|
Young Joo Min/Young Joo Min
Kwang Ro Joo/Neung Hwa Park/Tae Kwon Yun/Yang Won Nah*/Chang Woo Nam*/Jae Hoo Park
|
|
|
Abstract
|
|
|
Background: Advanced, unresectable pancreatic cancer is an extremely aggressive disease. The 5-year survival rate for pancreatic cancer is only less than 5%. Current therapeutic options for patients with locally advanced or metastatic disease are limited. This analysis is a retrospective evaluation of the efficacy and toxicity of gemcitabine regimen as first-line chemotherapy in patients with advanced pancreatic cancer.
Methods: Seventeen chemotherapy-naive patients with advanced or recurred pancreatic cancer were consecutively treated. Gemcitabine was diluted in normal saline and administered intravenously over 1 hour. Gemcitabine 1,000 mg/m2 was administered once weekly for 3 out of every 4 weeks.
Results: The median age of patients was 55 years (range 44?82 years). Based on RECIST criteria, there were 5 cases of stable disease (45%) and 6 cases of progressive disease (55%) among the 11 assessable patients. The median survival time was 189 days (range, 84 to 409 days), the 1 year survival rate was 18% in all 17 patients. Grade 3?4 toxic side effect was leucopenia only (29%) and was easily managed without infection.
Conclusion: Gemcitabine is well tolerated, but has no objective response in advanced pancreatic cancer.
|
|
|
KEYWORD
|
|
|
Pancreatic cancer, Gemcitabine,
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
    
|